Want to join the conversation?
$CELG said it has settled REVLIMID (lenalidomide) patent litigation with Natco Pharma of India. Under the deal, Natco to acquire license to sell generic lenalidomide in US without volume limitation beginning in Jan. 2026 & volume-limited entry beginning in March 2022 with anticipated mid-single-digit percentage of capsules sold in first 12 months.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.